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Background: Currently, there is no cure for Duchenne and Becker muscular dystrophies (DMD/BMD).
However, clinical trials with new therapeutic strategies are being conducted or considered. A comprehensive
database is critical for patient recruitment and efficacy evaluation. China has the largest population, yet, no
comprehensive database for DMD/BMD is available. Our study registered the data of the DMD/BMD patients
in East China.
Methods: A modified registry form of Remudy (http://www.remudy.jp/) was applied to Chinese DMD/BMD
patients through the outpatient clinic at Children’s Hospital of Fudan University, Shanghai during the period
of August 2011 to December 2013. The data included geographic distribution of patients, age at diagnosis,
clinical manifestation, genetic analysis and treatment status.
Results: 194 DMD and 35 BMD patients were registered. Most patients lived in East China, namely Jiangsu
province, Anhui province, Zhejiang province, Jiangxi province, Shanghai, Fujian province and Shandong
province. All individuals aged less than 18 years (age limit to a children’s hospital). Diagnosis was made for a
majority of patients during the age of 3–4 (16.6%) and 7–8 (14.8%) years old. Exon deletion was the most
frequent genetic mutations (65.5% and 74.3%) followed by point mutations (14.4% and 11.4%), duplications
(9.8% and 8.6%) and small insertion/deletion (9.3% and 2.9%) for DMD and BMD, respectively. 82.5% of DMD
registrants were ambulatory, and all the BMD registrants were able to walk. 26.3% of DMD registrants have
been treated with steroids. Cardiac functions were examined for 46.4% DMD boys and 45.7% BMD boys and
respiratory functions were examined for 18.6% DMD boys and 14.3% BMD boys. Four boys with abnormal
cardiac function were prescribed for treatment with cardiac medicine. 33.2% of DMD patients are eligible for
exon skipping therapy, and among them 9.2% and 4.3% patients are eligible for skipping exon 51 and 53,
respectively.
Conclusions: The database is the first linking accurate genetic diagnosis with clinical manifestation and
treatment status of dystrophinopathy patients in East China. It provides comprehensive information essential
for further patient management, especially for promotion of international cooperation in developing
experimental therapies such as exon skipping and read-through of nonsense mutations targeting a subgroup
of DMD patient population.
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Duchenne muscular dystrophy (DMD) and its milder
form, Becker muscular dystrophy (BMD) are X-linked
recessive muscular dystrophy caused by mutations in the
dystrophin gene (DMD) on chromosome Xp21.2 [1,2].
The DMD gene is the largest gene identified in human
and contains 79 exons. Patients with DMD have muta-
tions that result in no dystrophin protein production,
whereas those with BMD produce truncated but in-
frame dystrophin with decreased quantity and function
[3-5]. DMD is the most frequently inherited muscular
disease, affecting 1 in 3600–6000 live male births [6]. It
is characterized by progressive muscle weakness with
onset at 3–5 years of age, leading to loss of ambulation
by 10–12 years of age without treatment [7]. Respiratory,
orthopaedic, and cardiac complications emerge with age,
and without intervention, the mean age at death is
around 19 years [6]. BMD has a slower rate of progres-
sion with time of loss of ambulation from adolescence
onward to adulthood [8]. Some patients may continue
walking into their fifties or sixties and have a normal life
span [2,7].
Currently, although there is no effective treatment for
DMD, the natural history of the disease can be improved
by targeted interventions. Pharmacological and care-based
interventions (corticosteroid, rehabilitative, cardiac, ortho-
paedic, respiratory, and psychosocial interventions) are
proven to improve the muscle function, quality of life, and
longevity. Children with DMD who are diagnosed today
and receiving the generally recommended interventions
have the possibility of a life expectancy into their fourth
decade [6]. Moreover, promising therapeutic strategies are
being developed in animal models and human trials of
these strategies have started, leading to the hope of further
dramatic improvement for the disease. These therapeutic
strategies for DMD/BMD fall into four categories [9-12]:
(1) mutation-specific therapeutic approaches for repairing
the genetic defects or the transcripts (exon skipping, non-
sense codon suppression and endonuclease-mediated gene
correction); (2) gene replacement therapy, which can be
applied to the entire patient population; (3) cell therapy
including allogeneic stem cells with mutations corrected
ex vivo; and (4) modulation of non-dystrophin gene ex-
pression such as upregulation of utrophin to compensate
for the lack of dystrophin.
However, many of the therapeutic interventions target
only a subset of the DMD population with defined gen-
etic alteration. The best example is exon skipping. Each
antisense drug can only target a small population of
DMD with frame shift mutations correctable by the re-
moval of specific exon(s). Jerry R. Mendell et al. reported
that in prior open-label studies, eteplirsen, a phosphoro-
diamidate morpholino oligomer, enabled dystrophin pro-
duction in DMD with genetic mutations amenable toskipping exon 51. 12 DMD boys participated in this study
were reported with a 67.3 m benefit compared to placebo/
delayed patients (p ≤ 0.001) [13]. Recently, Bushby et al.
reported that Ataluren (Translarna™) offers promise as a
treatment for DMD with nonsense mutation [14].
With limited number of DMD/BMD subpopulation, it
becomes clear that, to meet general requirement by
regulatory authorities, clinical trial of targeted therapy
requires international collaboration to establish sufficient
patient enrollment for therapeutic significance to be
demonstrated statistically. Many countries have already
established national databases and collaborated with the
international registry of Treat-NMD [15]. However, aware-
ness of the disease and development of experimental ther-
apies in China lag far behind the industrialized nations
both in the medical circles and society in general. Few
medical institutions have specialized laboratories and phy-
sicians for diagnosis and treatment of DMD/BMD. In
addition, research funds specific for the diseases from both
private sectors and governmental organizations have been
almost non-existent in China until very recently. This has
led to a status where the epidemiological data and natural
history of the disease of a large patient population are
largely unmanaged. There is only one existing registry
website set up in September 2012 by General Hospital of
Chinese Armed Police Force, Beijing and China DMD
care and support association (www.dmd-registry.com) and
a DMD medical cooperation network has yet to be estab-
lished in China. Clearly, a comprehensive database for
Chinese DMD/BMD patients will be critical for care of
these patients and for international efforts to develop
experimental therapies. From August 2011, we started to
establish a database for DMD/BMD patients in Children’s
Hospital of Fudan University (named the CHFU database
for dystrophinopathy). The database has registered all the
DMD/BMD patients visiting the outpatient clinic of
CHFU. Here we described the registry with genetic diagno-
sis, clinical manifestation and the status of treatment. Fur-
ther expansion of the database in the country with the
largest population in the world will be undoubtedly highly
valuable for international cooperation to promote thera-
peutic research of the disease.
Methods
Institution and organization of the project
The CHFU database for dystrophinopathy is supported
by Children’s Hospital of Fudan University. The develop-
ment and management of the registry is led by the
Neuromuscular research unit, department of neurology.
Patients
The CHFU database includes DMD/BMD patients (all
male Chinese) whose diagnosis has been confirmed by gen-
etic analysis (see below section Phenotypic classification).
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China, namely Jiangsu, Anhui, Zhejiang, Shanghai, Jiangxi,
Fujian and Shandong.Method of registration and data collection
Information about the registry was provided to the pa-
tients diagnosed by genetic testing or muscle biopsy
through DMD Outpatient Clinic in our hospital. Patient
records were entered into the database on the basis of
informed consent, which explained the content and aims
of the database with voluntary registration. No identifi-
able personal data will be shared with any third party
without the patient’s permission and the subject will be
removed from the database immediately on request. This
study was approved by Pediatric Research Ethics Board
of Clinical Pharmacology Base, Fudan University.Structure of the registry form and patients’ follow-up
The registry form was designed with reference to the
registry form of Remudy (http://www.remudy.jp/) [16].
Data from individual patient include name, gender, date
of birth, address, phone number, family history related
to muscular dystrophy, results of biochemical analysis
(mainly serum creatine kinase levels) and muscle biopsy.
Detailed description of genetic mutation was also in-
cluded. Clinical symptoms include walking capability as
well as cardiac and respiratory functions. Treatment in-
cluding steroid therapy and history of scoliosis surgery
was recorded. All data were validated by molecular and
clinical curators. The database was semi-annually up-
dated by outpatient visits for ambulant patients and
through telephone follow-up for non-ambulant patients.Figure 1 Diagnostic process for muscular dystrophy in CHFU. The numPhenotypic classification
Classification of DMD or BMD is determined by neurol-
ogists and genetic curators together and based on gen-
etic analysis (reading frame rule) with consideration of
clinical information and histopathology including results
of dystrophin immunostaining if available (Figure 1).
MLPA analysis
MLPA (SALSA MLPA probemix P034-A3/P035-A3
DMD/Becker; MRC Holland, Amsterdam, Netherlands)
was the first-line method for the identification of muta-
tions in the dystrophin gene, allowing detection of dele-
tions or duplications in all 79 exons [17]. The data was
analyzed by Coffalyser MLPA analysis software. For sin-
gle exon deletion, further verification was carried out by
PCR and sequencing.
DHPLC and sequencing
DHPLC technique was applied to patients with negative
MLPA, but with confirmed diagnosis of DMD/BMD by
muscle biopsy. After amplification of the 79 primer
pairs, unpurified PCR amplicons from patients were
mixed in a 1:1 ratio with an aliquot of unpurified PCR
amplicon from an unaffected male. The mixture was
then denatured, followed by slowly cooling down in a
thermal cycler. The results were analyzed by the WAVE
nucleic fragment analysis system. The pre-treated ampli-
cons were processed at the optimal separation gradient
and temperature determined by WAVEMARKER 4.1
software. If a PCR amplicon presents a chromatogram
different from the control in shape or retention time, the
corresponding exon was then subjected to direct sequen-
cing to identify the position and the type of mutationsber in bracket is the total patients in various categories.
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National Center for Biotechnology Information (NCBI)
Gene database (dbSNP) was queried to identify the ex-
istence of the common SNPs, and polymerase chain
reaction-restriction fragment length polymorphism
(PCR-RFLP) was employed to identify the unreported
SNPs.
Dystrophin protein analysis
Muscle biopsies were analyzed by immunofluorescence for
dystrophin expression with each of the three NCL-DYS1,
NCL-DYS2 and NCL-DYS3 antibodies (Leica Biosystems
Newcastle). Patients with dystrophin recognized by NCL-
DYS2 against C-terminal region of the protein were con-
sidered as BMD [18].
Results
As of December 2013, 229 patients had registered in our
database with 194 DMD and 35 BMD with all individ-
uals less than 18 years old (Figure 2). All boys had gen-
etic diagnosis except 2 cases and 71.2% of patients had a
muscle biopsy. Diagnosis was made with higher propor-
tion during their age of 3–4 (16.6%) and 7–8 (14.8%)
years (Figure 3).
Most patients were from East China including Shanghai
(26) and the provinces surrounding Shanghai, namely
Jiangsu (57), Anhui (45), Zhejiang (30), Jiangxi (27), Fujian
(9) and Shandong (6). A small proportion of registrants
resided in South Central China (20), Southwest China (3),
Northwest China (3), North China (2) and Northeast
China (1) (Figure 4).
As summarized in Figure 5, Table 1 and Table 2, exon
deletion was the most frequent (65.5% and 74.3%) followed
by point mutations (14.4% and 11.4%), duplications (9.8%Figure 2 Ages of registered patients. All the registrants were under 18 yand 8.6%) and small insertion/deletion (9.3% and 2.9%) for
DMD and BMD, respectively. Two cases with no mutation
identified by MLPA and DHPLC were diagnosed as DMD
and BMD on the basis of muscle biopsy showing absence
of dystrophin expression and clinical manifestation. 33.2%
of DMD patients were eligible for exon skipping, among
whom 21 (9.2%) and 10 (4.3%) patients being eligible to
skipping of exon 51 and 53, respectively (Table 3).
Table 4 described the clinical characteristics of DMD/
BMD patients included in the registry. Among the DMD
registrants, 82.5% of boys were ambulant whereas all the
BMD registrants were ambulant. DMD patients lost
their walking ability from 9 to 12 years old. 25.3% of
DMD boys were receiving steroid treatment. Cardiac
functions were examined for 46.4% DMD boys and
45.7% BMD boys and respiratory functions were exam-
ined only for 18.6% DMD boys and 14.3% BMD boys.
The low percentage was related to the young age of the
majority of registrants. No abnormalities in cardiac func-
tions were detected in 44.3% of DMD and 45.7% of
BMD patients tested. Among the boys with cardiac dys-
function (diagnosed as dilated cardiomyopathy), three
boys with significant deficiency in left ventricular ejec-
tion fraction (25% to 48 % normal levels) and one boy
with abnormal ECG (electrocardiogram) were prescribed
with ACE–inhibitor treatment (1) and the ACE–inhibi-
tor and β-blocker (3). None of the patients used ventila-
tor support or received scoliosis surgery.
Discussion
Establishing a comprehensive database for DMD and
BMD requires wide collaborations and financial support.
With the strong support from Children’s Hospital of
Fudan University, we have been able to build a preliminaryears of age.
Figure 3 Age at diagnosis. 68.1% patients were diagnosed between the age of 2 to 8 years old.
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neurologist, rehabilitation specialist, physical therapist,
paediatric heart specialist, paediatric pulmonary specialist,
paediatric orthopaedist, geneticist and psychologist [6].
Currently, diagnosis has been made chiefly in our Molecu-
lar and Pathological Diagnostic Laboratory responsible for
genetic testing and immunohistochemical analyses of
muscle biopsy. This is coordinated by our DMD Out-
patient Clinic, which opened in January 2013 and focuses
on registry of clinical data, treatment regime and follow-
up. Since then, an increasing number of DMD/BMDFigure 4 Geographical distribution of 229 registrants. The number in bpatients were diagnosed and registered in the hospital. We
expect that our database will soon contain the largest
number of DMD/BMD patients in China and one of the
largest in the world. This will enhance the accuracy of
diagnosis, help in developing effective treatment and fa-
cilitate future clinical trials.
Age at diagnosis
Most of the registrants within the CHFU database were
diagnosed during the age of 3–4 (16.6%) and 7–8
(14.8%) years. The high rate of diagnosis at 3–4 year-oldracket is the total patients from the region.
Figure 5 Frequency of each exon (deletion and duplication) involved in DMD and BMD patients. Exons 45–52 were the most frequently
deleted for DMD patients and deletion of exons 45–47 was the most commonly involved for BMD patients.
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ing Nurseries and Kindergartens. However, the 7–8 year-
old children visited the outpatient clinic for clinical
symptoms typical for muscular dystrophy such as toe
walking and difficulty to climb stairs. Most boys of this
age group were from rural areas, indicating the lack of
awareness of the disease by both parents and primary
care doctors. The data raises the urgent need for health
authority and medical institutions to take initiative to
educate the public, especially in rural areas to improve
early diagnosis and provide preventive care and optimal
management.
Mutation distribution and genotype/phenotype
correlation
The large number of DMD/BMD patients in the CHFU
database also revealed the specific pattern of mutations
in the Chinese population. In this study, we analyzed the
distribution of individual exons based on their frequency
of deletion or duplication. Our data indicate that exonTable 1 Distribution of mutations in DMD/BMD patients
DMD patients BMD patients
Distribution
of mutation
No. of case % of case No. of case % of case
Deletion 127 65.5% 26 74.3%
Duplication 19 9.8% 3 8.6%
Deletion and
duplication
1 0.5% 0 0
Others* 46 23.7% 5 14.3%
No mutation
found**
1 0.5% 1 2.8%
194 100% 35 100%
*Point mutation, small insertion/deletion mutations and splice site mutations
are listed in Table 2. **Diagnosis was made on the basis of absence of
dystrophin expression and clinical manifestation.deletion is the most frequent followed by point muta-
tions, duplications and small insertion/deletion. In DMD
patients, exons 45–52 are the most frequently deleted.
This is similar to the pattern described in other data-
bases [16,17,20] and those of previously reported in
Chinese population [21-23]. Similarly, the most common
deletion in BMD patients was exons 45–47 (22.9%) [17].
In general, the severity of the phenotype correlates to
the reading-frame rule [24]. Similar to the report by Syl-
vie Tuffery-Giraud et al. [20], our database shows 95.2%
of DMD patients had out of frame or nonsense muta-
tions whereas 85.7% of the BMD mutations were in-
frame, consistent with two previous studies in Chinese
patients with DMD/BMD [21,22]. The phenotype for in-
frame mutations is to some extent determined by the
location and the size of the deletion. Large in-frame
deletions removing up to 35 exons in the central rod
domain have been described for patients with relatively
mild BMD [25,26]. Within our database, the muscle biopsy
of a patient with a large in-frame deletion of exons 27–57
showed absence of dystrophin expression using antibody
NCL-DYS1 (against amino acids 1181–1388), whereas near
normal level signals were detected using antibody NCL-
DYS2 and NCL-DYS3 (against amino acids 3669–3685
and 321–494 respectively). Another patient with a large
in-frame deletion of exons 10–41 showed absence of
dystrophin expression using antibody NCL-DYS1 and
NCL-DYS3, whereas near normal level signals were de-
tected using antibody NCL-DYS2. Both patients aged
8 years. No detectable muscle weakness was found and
the only pathological feature was the elevation of serum
creatine kinase (CK) (1926 U/L and 12350 U/L respect-
ively). Most point mutations are nonsense mutations
resulting in DMD. However, there were 2 BMD cases with
point mutations in our database (Seen in Table 2). One
5-year-old patient with the mutation c.3940C > T had
Table 2 Confirmed point mutations, small deletion/insertion of DMD/BMD patients
CHFU no. Phenotype Family history Exon/Intron Sequencing results Change of protein Carrier status of mother
7 DMD No Exo 19 c.2308A > T p.Lys770X Unknown
11 DMD No Exo 34 *c.4746_4747delCT p.Leu1583ThrfsX18 Unknown
12 DMD No Exo 19 c.2302C > T p.Arg768X Unknown
13 DMD Yes Exo 34 *c.4808_4809insGGAA p.Met1603GlufsX3 Yes
19 DMD Yes Exo 22 c.2816 T > A p.Leu939X Yes
20 DMD No Exo 17 c.2137C > T p.Gln713X Unknown
21 DMD No Exo 51 *c.7327_7328insA p.Asn2444SerfsX9 Unknown
22 DMD Yes Int 21 c.2803 + 1G > A Yes
26 DMD No Exo 33 c.4630delA p.Glu1545fs Unknown
33 DMD No Exo 16 *c.1886C > G p.Ser629X Unknown
42 DMD Yes Exo 60 c.8944C > T p.Arg2982X Yes
45 BMD No Int 17 *c.2169-1G > T Unknown
59 DMD No Exo 52 c.7657C > T p.Arg2553X Unknown
60 DMD No Exo 55 *c.8147-8148insCAGAAG p.His2717ArgfsX3 Unknown
CTGAAACAACTGCCAA
TGTCCTACA
61 DMD No Exo 13 c.1594C > T p.Gln532X Yes
62 BMD Yes Exo 4 *c.264_264 + 4delTGTAA p.Pro63_Asn88del Yes
64 DMD Yes Exo 64 *c.9297_9300dup p.Asn3100Asnfs Yes
67 BMD No Exo 25 c.3432G > T p.Gln1144His Unknown [19]
68 DMD No Exo 18 *c.2191delC p.Arg1288LeufsX7 Unknown
71 DMD No Exo 44 c.6292C > T p.Arg2098X Yes
74 DMD No Int 67 c.9807 + 5G > A Unknown
75 DMD No Exo 42 *c.6045delA p.Asp2016AsnfsX23 Unknown
79 DMD No Exo 64 c.9337C > T p.Arg3113X Unknown
80 BMD No Exo 25 *c.3388G > T p.Glu1130X Unknown
86 DMD No Exo 66 c.9568C > T p.Arg3190X Unknown
89 DMD No Exo 33 *c.4538-4541GTGAdel p.Lys1514fs Unknown
91 DMD No Int 54 *c.8028-1G > C Unknown
92 DMD Yes Exo 67 *c.9722_9723delCT p.Tyr3242ProfsX8 Yes
93 BMD No Exo 29 c.3940C > T p.Arg1314X Unknown
96 DMD Yes Exo 47 *c.6804_6807delACAA p.Asn2269fs Yes
97 DMD Yes Exo 59 c.8713C > T p.Arg2905X Yes
100 DMD No Exo 44 *c.6391_6392delCA p.Asn2132Leufs Unknown
101 DMD Yes Exo 10 c.998C > A p.Ser333X Yes
106 DMD No Exo 55 c.8038C > T p.Arg2680X Unknown
107 DMD No Exo 15 *c.1713insT p.Phe572fs No
113 DMD No Exo 64 c.9337C > T p.Arg3113X Unknown
114 DMD No Exo 42 *c.6033insTTAA p.Leu2012IlefsX11 Yes
127 DMD No Exo 19 *c.2300delA p.Gly768GlufsX25 Unknown
135 DMD Yes Exo 59 *c.8740G > T p.Glu2914X Yes
145 DMD Yes Exo 70 c.10171C > T p.Arg3391X Yes
148 DMD No Exo 52 c.7657C > T p.Arg2553X Unknown
161 DMD No Exo 10 *c.1033C > T p.Gln345X Yes
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Table 2 Confirmed point mutations, small deletion/insertion of DMD/BMD patients (Continued)
165 DMD No Exo 32 c.4483C > T p.Gln1495X Unknown
170 DMD Yes Exo 20 *c.2571delC p.Pro858ProfsX13 Yes
171 DMD No Int 14 c.1704 + 1G > C Yes
172 DMD No Exo 44 c.6292C > T p.Arg2098X Yes
177 DMD Yes Exo 12 *c.1412delC p.Lys472GlyfsX15 Yes
192 DMD No Exo 70 c.10108C > T p.Arg3370X Unknown
193 DMD No Exo 39 *c.5485C > T p.Gln1829X Unknown
197 DMD Yes Exo 64 *c.9297_9300dup p.Asn3100Asnfs Yes
201 DMD No Exo 70 c.10108C > T p.Arg3370X Unknown
Abbreviations: BMD Becker muscular dystrophy, DMD Duchenne muscular dystrophy, CHFU Children’s Hospital of Fudan University.
Asterisks indicate novel mutations that have not been previously reported in the Leiden Muscular Dystrophy database (updated 30 December 2013) (http://www.dmd.nl/).
Case no.64 is no.197’s uncle.
Table 4 Walking capability, medications and intervention
in the registrants with DMD and BMD
DMD patients BMD patients
No. of case % of case No. of case % of case
Walking capability
Normal walking 160 82.5% 35 100%
Not able to walk 34 17.5% 0 0
194 100% 35 100%
Cardiac function
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abnormality. Muscle biopsy showed lack of dystrophin
using antibody NCL-DYS1 against an epitope encoded
by exon 29, but positive staining using antibody NCL-
DYS2 and NCL-DYS3, consistent with the previous re-
port of a BMD family [27]. The other 4-year-old boy
with the novel point mutation (c.3388G > T) showed
the clinical abnormality of bringing the second foot up
to join the first rather than going foot over foot when
climbing stairs and high serum CK levels (9100 U/L).
The muscle biopsy showed lack of dystrophin using
antibody NCL-DYS1, NCL-DYS2 and NCL-DYS3. We
also found a large BMD pedigree with 4 patients and
10 carriers of a novel frame-shift mutation in exon 4 in
this family. The 5-year-old proband showed only mild
atrophy of bilateral quadriceps, without symptomatic
weakness. Muscle biopsy revealed mild myopathic features
including variation in fiber size and a few necrotic and re-
generating muscle fibers. Immunohistochemical analysis
demonstrated decreased expression with antibody NCL-
DYS3 and near normal expression with antibody NCL-Table 3 Candidates for 51 and 53 exon skipping for
restoration of dystrophin expression (source: www.
clinicaltrials.gov)













45-50 8 3.5% 52 3 1.3%
47-50 2 0.9% 47-52 1 0.4%
48-50 4 1.7% 48-52 3 1.3%
49-50 2 0.9% 49-52 2 0.9%
50 2 0.9% 50-52 1 0.4%
52 3 1.3%
52-63 0 0%
Total 21 9.2% 10 4.3%DYS1 and NCL-DYS2. Serum CK levels were consistently
around 2854 U/L. The oldest patient aged 35 was diag-
nosed at the age of 9 and lost walking ability in his thirties.
The other two patients aged 27 and 23 had the onset of
the disorder around 10 years old with difficulty in walking
and climbing stairs. All the patients revealed bilateral atro-
phy limited to quadriceps femoris without hypertrophy of
the calves. We considered it as quadriceps myopathy, a
clinical variant form of BMD [28-30].Normal 86 44.3% 16 45.7%
Dysfunction 4 2.1% 0 0
Not performed 104 53.6% 19 54.3%
194 100% 35 100%
Respiratory
function
Normal 36 18.6% 5 14.3%
Dysfunction 0 0 0 0
Not performed 158 81.4% 30 85.7%
194 100% 35 100%
Steriod use
Current 49 25.3% 2 5.7%
Used to 2 1% 0 0
Never 143 73.7% 33 94.3%
194 100% 35 100%
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In our study, 23.1% of the probands had a family medical
history of the disease and several pedigrees also had a
large number of patients and mutation carriers, espe-
cially in less developed areas. Through patient registry,
we provided information on genetic counseling and pre-
natal diagnosis for pedigrees and those who had given birth
to DMD/BMD babies to prevent this disease. 15 healthy
children have been born by prenatal diagnosis in these
families in 2013. Genetic counseling is therefore valuable
for prenatal diagnosis and vitally important to those big
families in less developed areas where literacy level is rela-
tively low and lack of knowledge about genetic diseases.
Steroid treatment and cardiac and pulmonary
management
26.3% of DMD patients in the database were treated
with steroids. This rate was relatively low compared to
that in the developed countries [16,31,32]. The main rea-
son for this is due to the lack of awareness of physicians
specialized in treating muscular dystrophies. The Family
Guide for the Diagnosis and Management of Duchenne
Muscular Dystrophy [33] became available in our hos-
pital only in January 2013, when DMD Outpatient Clinic
was opened. However, this environment is changing with
the establishment of the database and the adoption of
the TREAT-NMD project guidelines [6,34]. A steady in-
crease in the use of steroid treatment is expected in
China. As to the evaluation of cardiac and pulmonary
function, we refer to the Family Guide, which indicates
that baseline evaluation of cardiac function needs to be
performed at the confirmation of the diagnosis or at lat-
est by the age of six years. Evaluation includes an elec-
trocardiogram (ECG) and echocardiogram and occurs at
least once every two years until the age of ten. Yearly
complete cardiac evaluations begin at approximately ten
years of age or at the onset of cardiac signs and symp-
toms, if earlier. If noninvasive cardiac tests show abnor-
malities, increased surveillance is required, at least every
six months, and drug treatment will be initiated by our
cardiologists. In our database, four boys were prescribed
for treatment with ACE–inhibitor (1) and the ACE–in-
hibitor and β-blocker (3). One of them has an abnormal
ECG that showed right ventricular hypertrophy and
sinus tachycardia and the others have abnormal echocar-
diograms (ejection fraction ranging from 25-48% of nor-
mal levels) [31]. Minimal assessment of pulmonary
function (such as measurement of forced vital capacity
[FVC] at least annually) allows the child to become fa-
miliar with the equipment and the team to assess the
maximum respiratory function achieved, while a boy
with DMD is still walking. The main emphasis of pul-
monary assessment is after the loss of independent walk-
ing [33]. However, pulmonary management is far fromperfect in China. In our database, none of the patients
used ventilator support. No abnormality has been found
in the patients who received pulmonary function tests,
whereas most wheelchair-bound patients are taken care
of by their family members at home and are reluctant to
get tested. This is largely due to two factors: lack of
awareness by physicians of significance of these mea-
sures to the quality of patient’s life and lack of medical
insurance to cover the expenses in China. This rein-
forces the urgency to raise awareness of the disease to
the public, physicians and governmental organizations.Conclusions
The CHFU database is the most comprehensive one in
China and has the capacity to understand the natural his-
tory of DMD/BMD and facilitate international cooperation
in developing experimental therapies. This is especially im-
portant for clinical trials such as exon skipping targeting
only a subset of the patient population. For example, inter-
national cooperation is essential for any future clinical tri-
als of exon skipping targeting exons only applicable to less
than 5% of DMD population. A detailed database of pa-
tients is critical for providing a quick selection of patients
based on a pre-determined genotypic and phenotypic cri-
teria. In about two years, 229 DMD/BMD male patients
have registered in our database and 9.2% and 4.3% patients
are eligible for clinical trial focused on ‘skipping’ exon 51
and 53, respectively. 11.4% DMD/BMD male patients were
found to be suitable for the read-through of nonsense mu-
tations trial. Given the size of the population in China and
the rate of incidence, we hope, by extending the established
CHFU database, we will be able to make significant contri-
bution to the development of clinical trials and to promote
therapeutic research in China.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XL participated in planning and leading this study, curating the molecular
data and guiding the writing of the manuscript. LZ participated in data
entry, analysis and interpretation, generation of the tables and figures, in
writing of the manuscript. YW and SZ supervised the planning of this study
and participated in curating clinical data. CH, YS, WS, HL and FL participated
in curating clinical data and data collection. BW participated in genetic
analysis and curating the molecular data. All authors read and approved of
the final manuscript.
Authors’ information
Xihua Li and Lei Zhao are co-first authors.
Acknowledgments
This work was supported by Shanghai Charity Foundation (The Special Fund
for DMD). The authors thank all patients and their families for their
participation in this study. We also thank Anthony Blaeser (Cannon Research
Center, Carolinas Medical Center, Charlotte, NC, USA) for his text editing. We
particularly thank Qilong Lu (Cannon Research Center, Carolinas Medical
Center, Charlotte, NC, USA) for his advice and manuscript preparation.
Li et al. Orphanet Journal of Rare Diseases  (2015) 10:5 Page 10 of 10Author details
1Department of Neurology, Children’s Hospital of Fudan University, No.399,
Wanyuan Road, Minhang District, Shanghai 201102, China. 2Rehabilitation
Department, Children’s Hospital of Fudan University, Shanghai, China.
3Cardiac Center, Children’s Hospital of Fudan University, Shanghai, China.
4Translational Research Center for Development and Disease, Children’s
Hospital of Fudan University, Shanghai, China.
Received: 27 August 2014 Accepted: 29 December 2014References
1. Zubrzycka-Gaarn EE, Bulman DE, Karpati G, Burghes AH, Belfall B, Klamut HJ,
et al. The Duchenne muscular dystrophy gene product is localized in
sarcolemma of human skeletal muscle. Nature. 1988;333:466–9.
2. Davies KE, Smith TJ, Bundey S, Read AP, Flint T, Bell M, et al. Mild and severe
muscular dystrophy associated with deletions in Xp21 of the human X
chromosome. J Med Genet. 1988;25:9–13.
3. Brabec P, Vondracek P, Klimes D, Baumeister S, Lochmuller H, Pavlik T, et al.
Characterization of the DMD/BMD patient population in Czech Republic
and Slovakia using an innovative registry approach. Neuromuscul Disord.
2009;19:250–4.
4. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several
proteins, multiple phenotypes. Lancet Neurol. 2003;2:731–40.
5. Cunniff C, Andrews J, Meaney FJ, Mathews KD, Matthews D, Ciafaloni E,
et al. Mutation analysis in a population-based cohort of boys with Duchenne
or Becker muscular dystrophy. J Child Neurol. 2009;24:425–30.
6. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al.
Diagnosis and management of Duchenne muscular dystrophy, part 1:
diagnosis, and pharmacological and psychosocial management. Lancet
Neurol. 2010;9:77–93.
7. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, et al.
Exploring the molecular basis for variability among patients with Becker
muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet.
1991;49:54–67.
8. Ramelli GP, Joncourt F, Luetschg J, Weis J, Tolnay M, Burgunder JM.
Becker muscular dystrophy with marked divergence between clinical
and molecular genetic findings: case series. Swiss Med Wkly.
2006;18:189–93.
9. Benedetti S, Hoshiya H, Tedesco FS. Repair or replace? Exploiting novel
gene and cell therapy strategies for muscular dystrophies. FEBS J.
2013;280:4263–80.
10. Foster H, Popplewell L, Dickson G. Genetic therapeutic approaches for
Duchenne muscular dystrophy. Hum Gene Ther. 2012;23:676–87.
11. Moorwood C, Khurana TS. Duchenne muscular dystrophy drug discovery - the
application of utrophin promoter activation screening. Expert Opin Drug
Discov. 2013;8:569–81.
12. Govoni A, Magri F, Brajkovic S, Zanetta C, Faravelli I, Corti S, et al. Ongoing
therapeutic trials and outcome measures for Duchenne muscular dystrophy.
Cell Mol Life Sci. 2013;70:4585–602.
13. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al.
Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol.
2013;74:637–47.
14. Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren
treatment of patients with nonsense mutation dystrophinopathy. Muscle
Nerve. 2014;50:477–87.
15. Rodger S, Lochmuller H, Tassoni A, Gramsch K, Bushby K, Straub V, et al. The
TREAT-NMD care and trial site registry: an online registry to facilitate clinical
research for neuromuscular diseases. Orphanet J Rare Dis. 2013;8:171.
16. Nakamura H, Kimura E, Mori-Yoshimura M, Komaki H, Matsuda Y, Goto K,
et al. Characteristics of Japanese Duchenne and Becker muscular dystrophy
patients in a novel Japanese national registry of muscular dystrophy
(Remudy). Orphanet J Rare Dis. 2013;8:60.
17. Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y, et al.
Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker
muscular dystrophy cases from one Japanese referral center. J Hum Genet.
2010;55:379–88.
18. Arahata K, Beggs AH, Honda H, Ito S, Ishiura S, Tsukahara T, et al.
Preservation of the C-terminus of dystrophin molecule in the skeletal
muscle from Becker muscular dystrophy. J Neurol Sci. 1991;101:148–56.19. Wei X, Dai Y, Yu P, Qu N, Lan Z, Hong X, et al. Targeted next-generation
sequencing as a comprehensive test for patients with and female carriers
of DMD/BMD: a multi-population diagnostic study. Eur J Hum Genet.
2014;22:110–8.
20. Tuffery-Giraud S, Beroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L,
et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy
using the UMD-DMD database: a model of nationwide knowledgebase. Hum
Mutat. 2009;30:934–45.
21. Yang J, Li SY, Li YQ, Cao JQ, Feng SW, Wang YY, et al. MLPA-based
genotype-phenotype analysis in 1053 Chinese patients with DMD/BMD.
BMC Med Genet. 2013;14:29.
22. Chen WJ, Lin QF, Zhang QJ, He J, Liu XY, Lin MT, et al. Molecular analysis of
the dystrophin gene in 407 Chinese patients with Duchenne/Becker
muscular dystrophy by the combination of multiplex ligation-dependent
probe amplification and Sanger sequencing. Clin Chim Acta. 2013;423:35–8.
23. Wang X, Wang Z, Yan M, Huang S, Chen TJ, Zhong N. Similarity of DMD
gene deletion and duplication in the Chinese patients compared to global
populations. Behav Brain Funct. 2008;4:20.
24. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation
for the phenotypic differences between patients bearing partial deletions of
the DMD locus. Genomics. 1988;2:90–5.
25. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, et al.
The molecular basis for Duchenne versus Becker muscular dystrophy: correlation
of severity with type of deletion. Am J Hum Genet. 1989;45:498–506.
26. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den
Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation
database: an overview of mutation types and paradoxical cases that confirm
the reading-frame rule. Muscle Nerve. 2006;34:135–44.
27. Ginjaar IB, Kneppers AL, v d Meulen JD, Anderson LV, Bremmer-Bout M, van
Deutekom JC, et al. Dystrophin nonsense mutation induces different levels
of exon 29 skipping and leads to variable phenotypes within one BMD family.
Eur J Hum Genet. 2000;8:793–6.
28. Kumari D, Gupta M, Goyle S. Detection of deletion in the dystrophin gene
of a patient with quadriceps myopathy. Neurol India. 2000;48:68–71.
29. Wada Y, Itoh Y, Furukawa T, Tsukagoshi H, Arahata K. “Quadriceps
myopathy”: a clinical variant form of Becker muscular dystrophy. J Neurol.
1990;237:310–2.
30. Sunohara N, Arahata K, Hoffman EP, Yamada H, Nishimiya J, Arikawa E, et al.
Quadriceps myopathy: forme fruste of Becker muscular dystrophy. Ann
Neurol. 1990;28:634–9.
31. Spurney C, Shimizu R, Morgenroth LP, Kolski H, Gordish-Dressman H, Clemens
PR, et al. Cooperative international neuromuscular research group Duchenne
natural history study demonstrates insufficient diagnosis and treatment of
cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve.
2014;50:250–6.
32. Matthews DJ, James KA, Miller LA, Pandya S, Campbell KA, Ciafaloni E, et al.
Use of corticosteroids in a population-based cohort of boys with duchenne
and becker muscular dystrophy. J Child Neurol. 2010;25:1319–24.
33. The family guide for the diagnosis and management of DMD. Available at:
http://www.treat-nmd.eu/care/dmd/family-guide/translations/. Accessed
April 26, 2014.
34. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al.
Diagnosis and management of Duchenne muscular dystrophy, part 2:
implementation of multidisciplinary care. Lancet Neurol. 2010;9:177–89.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
